Skip to main content

Table 2 Clinical characteristics and PD-L1 expression in concurrent gene alteration patients

From: Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma

Case Gender Age Stage Smoking Gene type PD-L1 expression OS (month)
1 Male 43 IB Yes EGFR+PIK3CA Yes 67+
2 Female 51 IIIA No RET+PIK3CA Yes 42
3 Female 58 IIIA No EGFR+ALK Yes 34
4 Male 74 IA No EGFR+PIK3CA No 66+
5 Male 60 IIIA Yes KRAS+ALK Yes 35+
6 Female 60 IB No EGFR+RET-M2 Yes 54
7 Female 60 IA No EGFR+PIK3CA Yes 36+
8 Male 64 IIA No RET+PIK3CA No 55
9 Male 69 IB No KRAS6+HER2 Yes 43+
10 Male 45 IIIA Yes KRAS+PIK3CA Yes 25
11 Female 64 IIB Yes EGFR+HER2 No 46+
12 Female 75 IIIA No EGFR+PIK3CA No 24+
13 Female 69 IIA No KRAS+PIK3CA Yes 36
14 Female 49 IB No EGFR+HER2 Yes 48+
15 Female 55 IIB Yes ROS1+HER2 Yes 37+
16 Male 62 IB Yes EGFR+ALK No 46
17 Male 55 IIIA No EGFR+PIK3CA Yes 39
18 Female 68 IB No EGFR+PIK3CA Yes 58+
19 Female 76 IB No ALK+RET-M16 No 28
20 Male 43 IB No EGFR+PIK3CA Yes 55+
21 Male 59 IIIA Yes KRAS+PIK3CA Yes 18+
22 Female 61 IB No EGFR+PIK3CA Yes 66+
23 Female 68 IIA No EGFR+HER2 Yes 45
24 Male 62 IIIA Yes KRAS+HER2 Yes 16